Abstract: The current invention provides a system for managing resources like application modules, databases, information repositories etc., monitoring transactions and transmitting data among systems. The system comprises a policy definition layer, a policy deployment layer and a policy execution layer. The policy definition layer provides for creating, editing and visualizing policies through a user interface using intuitive simple language constructs. The policy deployment layer converts the created policies into a relational format that can be directly stored in a policy database. The policy execution layer executes the deployed policies on occurrence of an event. A resource abstraction and notification layer provides the interfacing of the resources with the policy definition layer, policy deployment layer and the policy execution layer.

Abstract: The invention describes a method and system to optimize network bandwidth and obtain greater efficiency in transmission of messages/data in, a client-server network. The invention proposes the use of clustering of client requests and the data items in such a manner so as to optimize the network transmission as well as reduce the cost of processing involved in sending and picking/pruning the data items at server and client end respectively.

Abstract: Compounds of general formula (I): wherein R1, Y, (X)0, (W)n, (V)m, Z and U are as defined in the specification, are inhibitors of cruzipain and other cysteine protease inhibitors and are useful as therpeutic agents, for example in Chagas' disease, or for validating therapeutic target compounds.

Abstract: A system, method, and apparatus for dynamically booting processor code memory with a wait instruction is presented herein. A wait instruction precedes the transfer of a new code portion to the code memory. The wait instruction causes the processor to temporarily cease using the code memory. When the processor ceases using the code memory, the processor signals a direct memory access (DMA) module to transfer a new code portion to the code memory. The DMA module transfers the new code portion to the code memory and transmits a signal to the processor when the transfer is completed. The signal causes the processor to resume. When the processor resumes, the processor begins executing the instructions at the next code address.

Abstract: The invention provides isolated nucleic acid molecules encoding polypeptides having 2,5-DKG permease activity, and oligonucleotides therefrom. The isolated nucleic acid molecules can be expressed in appropriate bacterial cells to enhance the production of 2-KLG, which can subsequently be converted to ascorbic acid. Further provided are isolated polypeptides having 2,5-DKG permease activity, immunogenic peptides therefrom, and antibodies specific therefor. The invention also provides methods of identifying novel 2,5-DKG permeases.

Abstract: A voltage level translator for digital logic circuits provides high level to low level voltage translation with equal rise and fall delays. The voltage level translator may include an input high voltage logic inverter (operating at the high voltage level) and connected to an output low voltage logic inverter operating at the low voltage level via a voltage reduction circuit. A related method for providing high level to low voltage translation may include providing an input inverter operating at the high voltage level and an output inverter operating at the low voltage level. Furthermore, the output of the high voltage inverter may be coupled to the input of the low voltage inverter after reducing the output voltage of the high voltage inverter to the required level.

Abstract: The present invention relates to a bioenhancing/bioavailability-facilitating composition comprising:

Abstract: Selecting one or more marketing messages for optimal display at marketing locations in a marketing environment is performed on the basis of information relating to a user to whom the messages are to be displayed, the marketing messages, and the marketing locations. Dynamic selection and display of marketing messages in this manner can be advantageously performed for online environments for which relevant information is readily accessed and used as a basis for selection and display of marketing messages.

Abstract: A voltage level translator for digital logic circuits provides high level to low level voltage translation with equal rise and fall delays. The voltage level translator may include an input high voltage logic inverter (operating at the high voltage level) and connected to an output low voltage logic inverter operating at the low voltage level via a voltage reduction circuit. A related method for providing high level to low voltage translation may include providing an input inverter operating at the high voltage level and an output inverter operating at the low voltage level. Furthermore, the output of the high voltage inverter may be coupled to the input of the low voltage inverter after reducing the output voltage of the high voltage inverter to the required level.

Abstract: The invention provides isolated nucleic acid molecules encoding polypeptides having 2,5-DKG permease activity, and oligonucleotides therefrom. The isolated nucleic acid molecules can be expressed in appropriate bacterial cells to enhance the production of 2-KLG, which can subsequently be converted to ascorbic acid. Further provided are isolated polypeptides having 2,5-DKG permease acitivity, immunogenic peptides therefrom, and antibodies specific therefor. The invention also provides methods of identifying novel 2,5-DKG permeases.

Abstract: A method for enhancing a host cell's biosynthetic production of 2-KLG is described. Such method comprises selecting a host cell that has an at least partially intracellular synthetic pathway which utilizes 2,5-DKG to produce 2-KLG; increasing the transport of said 2,5-DKG into said host cell while maintaining the integrity of the host cell; culturing the host cell to produce said 2,5-DKG; and producing 2-KLG. The transport of the 2,5-DKG is increased by transforming into the host cell DNA encoding for one or more enzymes transporting the 2,5-DKG into the host cell.

Abstract: Methods for forming repeat protein polymers and utilizing the repeat protein polymers to form inorganic structures are provided. The inorganic structures may have features on the nanoscale, and the structures generally do not have the repeat protein polymers incorporated therein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that is will not be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).

Abstract: The present invention relates to a controlled release pharmaceutical composition comprising amounts ranging from about 0.1 to about 4.5% w/w, of one or more of rate controlling cellulosic ether polymers.

Abstract: The present invention relates to the use of extracts of Carum carvi as bioenhancers, either alone or in combination with piperine or Zinzeber officinale extract to improve the bioavailability of a wide variety of drugs.

Abstract: A semiconductor device and process for making the same are disclosed which use reticulated conductors and a width-selective planarizing interlevel dielectric (ILD) deposition process to improve planarity of an interconnect layer. Reticulated conductor 52 is used in place of a solid conductor where the required solid conductor width would be greater than a process and design dependent critcal width (conductors smaller than the critical width may be planarized by an appropriate ILD deposition). The reticulated conductor is preferably formed of integrally-formed conductive segments with widths less than the critical width, such that an ILD 32 formed by a process such as a high density plasma oxide deposition (formed by decomposition of silane in an oxygen-argon atmosphere with a back-sputtering bias) or spin-coating planarizes the larger, reticulated conductor as it would a solid conductor of less than critical width. Using such a technique, subsequent ILD planarization steps by, e.g.

Abstract: The present invention relates to an extended release formulation comprising a coated drug containing core, wherein the coating is an aqueous coating, comprising an aqueous polymer dispersion of a water-insoluble film forming polymer in combination with an aqueous colloidal solution of a high viscosity swellable polymer.

Abstract: The present invention provides means for the production of desired end-products of in vitro and/or in vivo bioconversion of biomass-based feed stock substrates, including but not limited to such materials as starch and cellulose. In particularly preferred embodiments, the methods of the present invention do not require gelatinization and/or liquefaction of the substrate.

Abstract: A set of auctions is divided into groups of auctions such that the chances of finding interesting auctions across the groups of auctions by a bidder are minimized. These groups of auctions can scheduled such that the chances of auctions of interest to bidders (and prospective bidders) held in the same time slot or are either minimised or maximized.

Abstract: The present invention relates to a controlled release pharmaceutical composition comprising amounts ranging from about 0.1 to about 4.5% w/w, of one or more of rate controlling cellulosic ether polymers.

Abstract: A pharmaceutical formulation having improved bioavailability and bioequivalence includes particles of amorphous and/or crystalline atorvastatin that have a particle size (d90) less than 150 &mgr;m and a mean particle size (d50) of the atorvastatin particles that is between approximately 5 and 50 &mgr;m. The atorvastatin can be one or more of atorvastatin calcium, atorvastatin magnesium, atorvastatin aluminum, atorvastatin iron, and atorvastatin zinc. The formulations of atorvastatin can be stabilized by mixing atorvastatin with an alkali metal salt additive at between approximately 1.2% and less than 5% w/w of the formulation.